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Abstract
The CONSORT statement is used worldwide to improve the reporting of randomised controlled trials. Kenneth
Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on
new methodological evidence and accumulating experience.
To encourage dissemination of the CONSORT 2010 Statement, this article is freely accessible on bmj.com and will
also be published in the Lancet, Obstetrics and Gynecology, PLoS Medicine, Annals of Internal Medicine, Open
Medicine, Journal of Clinical Epidemiology, BMC Medicine, and Trials.
Introduction
Randomised controlled trials, when appropriately
designed, conducted, and reported, represent the gold
standard in evaluating healthcare interventions. How-
ever, randomised trials can yield biased results if they
lack methodological rigour [1]. To assess a trial accu-
rately, readers of a published report need complete,
clear, and transparent information on its methodology
and findings. Unfortunately, attempted assessments fre-
quently fail because authors of many trial reports
neglect to provide lucid and complete descriptions of
that critical information [2-4].
That lack of adequate reporting fuelled the develop-
ment of the original CONSORT (Consolidated Stan-
dards of Reporting Trials) statement in 1996 [5] and its
revision five years later [6-8]. While those statements
improved the reporting quality for some randomised
controlled trials, [9,10] many trial reports still remain
inadequate [2]. Furthermore, new methodological evi-
dence and additional experience has accumulated since
the last revision in 2001. Consequently, we organised a
CONSORT Group meeting to update the 2001 state-
ment [6-8]. We introduce here the result of that pro-
cess, CONSORT 2010.
Intent of CONSORT 2010
The CONSORT 2010 Statement is this paper including
the 25 item checklist in the table (Table 1) and the flow
diagram (Figure 1). It provides guidance for reporting all
randomised controlled trials, but focuses on the most
common design type-individually randomised, two
group, parallel trials. Other trial designs, such as cluster
randomised trials and non-inferiority trials, require vary-
ing amounts of additional information. CONSORT
extensions for these designs, [11,12] and other CON-
SORT products, can be found through the CONSORT
website http://www.consort-statement.org. Along with
the CONSORT statement, we have updated the explana-
tion and elaboration article, [13] which explains the
inclusion of each checklist item, provides methodologi-
cal background, and gives published examples of trans-
parent reporting.
Diligent adherence by authors to the checklist items
facilitates clarity, completeness, and transparency of
reporting. Explicit descriptions, not ambiguity or omis-
sion, best serve the interests of all readers. Note that the
CONSORT 2010 Statement does not include recom-
mendations for designing, conducting, and analysing
trials. It solely addresses the reporting of what was done
and what was found.
Nevertheless, CONSORT does indirectly affect design
and conduct. Transparent reporting reveals deficiencies
in research if they exist. Thus, investigators who con-
duct inadequate trials, but who must transparently
report, should not be able to pass through the publica-
tion process without revelation of their trial’s inadequa-
cies. That emerging reality should provide impetus to
improved trial design and conduct in the future, a
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SORT can help researchers in designing their trial.
Background to CONSORT
Efforts to improve the reporting of randomised con-
trolled trials accelerated in the mid-1990s, spurred
partly by methodological research. Researchers had
shown for many years that authors reported such trials
poorly, and empirical evidence began to accumulate
that some poorly conducted or poorly reported aspects
of trials were associated with bias [14]. Two initiatives
aimed at developing reporting guidelines culminated in
one of us (DM) and Drummond Rennie organising the
first CONSORT statement in 1996 [5]. Further metho-
dological research on similar topics reinforced earlier
findings [15] and fed into the revision of 2001 [6-8].
Subsequently, the expanding body of methodological
research informed the refinement of CONSORT 2010.
More than 700 studies comprise the CONSORT data-
base (located on the CONSORT website), which pro-
vides the empirical evidence to underpin the
CONSORT initiative.
Indeed, CONSORT Group members continually
monitor the literature. Information gleaned from these
efforts provides an evidence base on which to update
the CONSORT statement. We add, drop, or modify
items based on that evidence and the recommendations
of the CONSORT Group, an international and eclectic
group of clinical trialists, statisticians, epidemiologists,
and biomedical editors. The CONSORT Executive (KFS,
DGA, DM) strives for a balance of established and
emerging researchers. The membership of the group is
dynamic. As our work expands in response to emerging
projects and needed expertise, we invite new members
to contribute. As such, CONSORT continually assimi-
lates new ideas and perspectives. That process informs
the continually evolving CONSORT statement.
Over time, CONSORT has garnered much support.
More than 400 journals, published around the world
and in many languages, have explicitly supported the
CONSORT statement. Many other healthcare journals
support it without our knowledge. Moreover, thousands
more have implicitly supported it with the endorsement
of the CONSORT statement by the International Com-
mittee of Medical Journal Editors http://www.icmje.org.
Other prominent editorial groups, the Council of
Science Editors and the World Association of Medical
Editors, officially support CONSORT. That support
Figure 1 Flow diagram of the progress through the phases of a parallel randomised trial of two groups (that is, enrolment,
intervention allocation, follow-up, and data analysis).
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CONSORT seems to improve reporting [9].
Development of CONSORT 2010
Thirty one members of the CONSORT 2010 Group met
in Montebello, Canada, in January 2007 to update the
2001 CONSORT statement. In addition to the accumu-
lating evidence relating to existing checklist items, sev-
eral new issues had come to prominence since 2001.
Some participants were given primary responsibility for
aggregating and synthesising the relevant evidence on a
particular checklist item of interest. Based on that evi-
dence, the group deliberated the value of each item. As
in prior CONSORT versions, we kept only those items
deemed absolutely fundamental to reporting a rando-
mised controlled trial. Moreover, an item may be funda-
mental to a trial but not included, such as approval by
an institutional ethical review board, because funding
bodies strictly enforce ethical review and medical jour-
nals usually address reporting ethical review in their
instructions for authors. Other items may seem desir-
able, such as reporting on whether on-site monitoring
was done, but a lack of empirical evidence or any con-
sensus on their value cautions against inclusion at this
point. The CONSORT 2010 Statement thus addresses
the minimum criteria, although that should not deter
authors from including other information if they con-
sider it important.
After the meeting, the CONSORT Executive convened
teleconferences and meetings to revise the checklist.
After seven major iterations, a revised checklist was dis-
tributed to the larger group for feedback. With that
feedback, the executive met twice in person to consider
all the comments and to produce a penultimate version.
That served as the basis for writing the first draft of this
paper, which was then distributed to the group for feed-
back. After consideration of their comments, the execu-
tive finalised the statement.
The CONSORT Executive then drafted an updated
explanation and elaboration manuscript, with assistance
from other members of the larger group. The substance
of the 2007 CONSORT meeting provided the material
for the update. The updated explanation and elaboration
manuscript was distributed to the entire group for addi-
tions, deletions, and changes. That final iterative process
converged to the CONSORT 2010 Explanation and Ela-
boration [13].
Changes in CONSORT 2010
The revision process resulted in evolutionary, not revo-
lutionary, changes to the checklist (Table 1), and the
flow diagram was not modified except for one word
(Figure 1). Moreover, because other reporting guidelines
augmenting the checklist refer to item numbers, we
kept the existing items under their previous item num-
bers except for some renumbering of items 2 to 5. We
added additional items either as a sub-item under an
existing item, an entirely new item number at the end
of the checklist, or (with item 3) an interjected item into
a renumbered segment. We have summarised the note-
worthy general changes in Appendix 1 and specific
changes in Appendix 2. The CONSORT website con-
tains a side by side comparison of the 2001 and 2010
versions.
Implications and limitations
We developed CONSORT 2010 to assist authors in
writing reports of randomised controlled trials, editors
and peer reviewers in reviewing manuscripts for publica-
tion, and readers in critically appraising published arti-
cles. The CONSORT 2010 Explanation and Elaboration
provides elucidation and context to the checklist items.
We strongly recommend using the explanation and ela-
boration in conjunction with the checklist to foster
complete, clear, and transparent reporting and aid
appraisal of published trial reports.
CONSORT 2010 focuses predominantly on the two
group, parallel randomised controlled trial, which
accounts for over half of trials in the literature [2]. Most
of the items from the CONSORT 2010 Statement, how-
ever, pertain to all types of randomised trials. Neverthe-
less, some types of trials or trial situations dictate the
need for additional information in the trial report.
When in doubt, authors, editors, and readers should
consult the CONSORT website for any CONSORT
extensions, expansions (amplifications), implementa-
tions, or other guidance that may be relevant.
The evidence based approach we have used for CON-
SORT also served as a model for development of other
reporting guidelines, such as for reporting systematic
reviews and meta-analyses of studies evaluating inter-
ventions [16], diagnostic studies [17], and observational
studies [18]. The explicit goal of all these initiatives is to
improve reporting. The Enhancing the Quality and
Transparency of Health Research (EQUATOR) Network
will facilitate development of reporting guidelines and
help disseminate the guidelines: http://www.equator-
network.org provides information on all reporting guide-
lines in health research.
With CONSORT 2010, we again intentionally declined
to produce a rigid structure for the reporting of rando-
mised trials. Indeed, SORT [19] tried a rigid format, and
it failed in a pilot run with an editor and authors [20].
Consequently, the format of articles should abide by
journal style, editorial directions, the traditions of the
research field addressed, and, where possible, author
preferences. We do not wish to standardise the structure
of reporting. Authors should simply address checklist
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Section/Topic Item
No
Checklist item Reported on
page No
Title and abstract
1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results, and conclusions (for specific
guidance see CONSORT for abstracts [21,31])
Introduction
Background and objectives 2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio
3b Important changes to methods after trial commencement (such as eligibility criteria), with
reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details to allow replication, including how
and when they were actually administered
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including
how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomisation:
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as blocking and block size)
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation sequence (such as sequentially
numbered containers), describing any steps taken to conceal the sequence until
interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who
assigned participants to interventions
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care
providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant flow (a diagram is
strongly recommended)
13a For each group, the numbers of participants who were randomly assigned, received
intended treatment, and were analysed for the primary outcome
13b For each group, losses and exclusions after randomisation, together with reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and
whether the analysis was by original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the estimated
effect size and its precision (such as 95% confidence interval)
17b For binary outcomes, presentation of both absolute and relative effect sizes is
recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted
analyses, distinguishing pre-specified from exploratory
Harms 19 All important harms or unintended effects in each group (for specific guidance see
CONSORT for harms [28])
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant,
multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the trial findings
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lucidity. That stated, we think that manuscripts benefit
from frequent subheadings within the major sections,
especially the methods and results sections.
CONSORT urges completeness, clarity, and transpar-
ency of reporting, which simply reflects the actual trial
design and conduct. However, as a potential drawback,
a reporting guideline might encourage some authors to
report fictitiously the information suggested by the gui-
dance rather than what was actually done. Authors, peer
reviewers, and editors should vigilantly guard against
that potential drawback and refer, for example, to trial
protocols, to information on trial registers, and to regu-
latory agency websites. Moreover, the CONSORT 2010
Statement does not include recommendations for
designing and conducting randomised trials. The items
should elicit clear pronouncements of how and what the
authors did, but do not contain any judgments on how
and what the authors should have done. Thus, CON-
SORT 2010 is not intended as an instrument to evaluate
the quality of a trial. Nor is it appropriate to use the
checklist to construct a “quality score.”
Nevertheless, we suggest that researchers begin trials
with their end publication in mind. Poor reporting
allows authors, intentionally or inadvertently, to escape
scrutiny of any weak aspects of their trials. However,
with wide adoption of CONSORT by journals and edi-
torial groups, most authors should have to report trans-
parently all important aspects of their trial. The ensuing
scrutiny rewards well conducted trials and penalises
poorly conducted trials. Thus, investigators should
understand the CONSORT 2010 reporting guidelines
before starting a trial as a further incentive to design
and conduct their trials according to rigorous standards.
CONSORT 2010 supplants the prior version published
in 2001. Any support for the earlier version accumulated
from journals or editorial groups will automatically
extend to this newer version, unless specifically
requested otherwise. Journals that do not currently sup-
port CONSORT may do so by registering on the CON-
SORT website. If a journal supports or endorses
CONSORT 2010, it should cite one of the original
versions of CONSORT 2010, the CONSORT 2010
Explanation and Elaboration, and the CONSORT web-
site in their “Instructions to authors.” We suggest that
authors who wish to cite CONSORT should cite this or
another of the original journal versions of CONSORT
2010 Statement, and, if appropriate, the CONSORT
2010 Explanation and Elaboration [13]. All CONSORT
material can be accessed through the original publishing
journals or the CONSORT website. Groups or indivi-
duals who desire to translate the CONSORT 2010 State-
ment into other languages should first consult the
CONSORT policy statement on the website.
We emphasise that CONSORT 2010 represents an
evolving guideline. It requires perpetual reappraisal and,
if necessary, modifications. In the future we will further
revise the CONSORT material considering comments,
criticisms, experiences, and accumulating new evidence.
We invite readers to submit recommendations via the
CONSORT website.
Appendix 1: Noteworthy general changes in
CONSORT 2010 Statement
￿ We simplified and clarified the wording, such as in
items 1, 8, 10, 13, 15, 16, 18, 19, and 21
￿ We improved consistency of style across the items
by removing the imperative verbs that were in the 2001
version
￿ We enhanced specificity ofa p p r a i s a lb yb r e a k i n g
some items into sub-items. Many journals expect
authors to complete a CONSORT checklist indicating
where in the manuscript the items have been
addressed. Experience with the checklist noted prag-
matic difficulties when an item comprised multiple
elements. For example, item 4 addresses eligibility of
participants and the settings and locations of data
collection. With the 2001 version, an author could
provide a page number for that item on the checklist,
but might have reported only eligibility in the paper,
for example, and not reported the settings and
locations. CONSORT 2010 relieves obfuscations
and forces authors to provide page numbers in the
checklist for both eligibility and settings.
Table 1: CONSORT 2010 checklist of information to include when reporting a randomised trial* (Continued)
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other
relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration [13] for important clarifications on all the
items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials [11], non-inferiority and equivalence trials [12], non-
pharmacological treatments [32], herbal interventions [33], and pragmatic trials [34]. Additional extensions are forthcoming: for those and for up to date
references relevant to this checklist, see http://www.consort-statement.org/.
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CONSORT 2010 Statement
Item 1b (title and abstract)- W ea d d e das u b - i t e mo n
providing a structured summary of trial design, meth-
ods, results, and conclusions and referenced the CON-
SORT for abstracts article [21].
Item 2b (introduction)-We added a new sub-item (for-
merly item 5 in CONSORT 2001) on “Specific objectives
or hypotheses”
Item 3a (trial design)-We added a new item including
this sub-item to clarify the basic trial design (such as par-
allel group, crossover, cluster) and the allocation ratio
Item 3b (trial design)-We added a new sub-item that
addresses any important changes to methods after trial
commencement, with a discussion of reasons
Item 4 (participants)-Formerly item 3 in CONSORT
2001
Item 5 (interventions)-Formerly item 4 in CONSORT
2001. We encouraged greater specificity by stating that
descriptions of interventions should include “sufficient
details to allow replication”[3]
Item 6 (outcomes)-We added a sub-item on identifying
any changes to the primary and secondary outcome
(endpoint) measures after the trial started. This followed
from empirical evidence that authors frequently provide
analyses of outcomes in their published papers that
were not the prespecified primary and secondary out-
comes in their protocols, while ignoring their prespeci-
fied outcomes (that is, selective outcome reporting)
[4,22]. We eliminated text on any methods used to
enhance the quality of measurements
Item 9 (allocation concealment mechanism)-We
reworded this to include mechanism in both the report
topic and the descriptor to reinforce that authors should
report the actual steps taken to ensure allocation con-
cealment rather than simply report imprecise, perhaps
banal, assurances of concealment
Item 11 (blinding)-We added the specification of how
blinding was done and, if relevant, a description of the
similarity of interventions and procedures. We also elimi-
nated text on “how the success of blinding (masking) was
assessed” because of a lack of empirical evidence support-
ing the practice as well as theoretical concerns about the
validity of any such assessment [23,24]
Item 12a (statistical methods)-We added that statisti-
cal methods should also be provided for analysis of sec-
ondary outcomes
Sub-item 14b (recruitment)-Based on empirical
research, we added a sub-item on “Why the trial ended
or was stopped” [25]
Item 15 (baseline data)-We specified “A table” to clar-
ify that baseline and clinical characteristics of each
group are most clearly expressed in a table
Item 16 (numbers analysed)-We replaced mention of
“intention to treat” analysis, a widely misused term, by a
more explicit request for information about retaining
participants in their original assigned groups [26]
Sub-item 17b (outcomes and estimation)-For appropri-
ate clinical interpretability, prevailing experience sug-
gested the addition of “For binary outcomes,
presentation of both relative and absolute effect sizes is
recommended” [27]
Item 19 (harms)-We included a reference to the CON-
SORT paper on harms [28]
Item 20 (limitations)- W ec h a n g e dt h et o p i cf r o m
“Interpretation” and supplanted the prior text with a
sentence focusing on the reporting of sources of poten-
tial bias and imprecision
Item 22 (interpretation)-We changed the topic from
“Overall evidence.” Indeed, we understand that authors
should be allowed leeway for interpretation under this
nebulous heading. However, the CONSORT Group
expressed concerns that conclusions in papers fre-
quently misrepresented the actual analytical results and
that harms were ignored or marginalised. Therefore, we
changed the checklist item to include the concepts of
results matching interpretations and of benefits being
balanced with harms
Item 23 (registration)-We added a new item on trial
registration. Empirical evidence supports the need for
trial registration, and recent requirements by journal
editors have fostered compliance [29]
Item 24 (protocol)-We added a new item on availabil-
ity of the trial protocol. Empirical evidence suggests that
authors often ignore, in the conduct and reporting of
their trial, what they stated in the protocol [4,22].
Hence, availability of the protocol can instigate adher-
ence to the protocol before publication and facilitate
assessment of adherence after publication
Item 25 (funding)-We added a new item on funding.
Empirical evidence points toward funding source
sometimes being associated with estimatedeatment
effects [30]
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